Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis

Background: Apatinib is a novel tyrosine kinase inhibitor used in the treatment of advanced hepatocellular carcinoma (HCC). For decades, sorafenib has been a classic first-line treatment option for patients with HCC. This meta-analysis aimed to assess the efficacy and safety of apatinib versus sorafenib/placebo as first-line treatment for intermediate and advanced primary liver cancer (PLC). Methods: A literature search was performed via PubMed, Web of Science, CENTRAL, Embase, CNKI, VIP, and CBM. Data extraction from databases of other languages is not restricted. The Cochrane risk of bias tool, modified Jadad scale, Newcastle–Ottawa scale (NOS), and non-randomized studies of interventions (ROBINS-I) tool were employed to evaluate methodological qualities in original studies. Influence analysis was applied to assess the reliability of pooled results. Publication bias was evaluated using the funnel plot with Begg’s test and Egger’s test. Results: Seven studies were included in the systematic review and meta-analysis. Four randomized controlled trials (RCTs) and one clinical controlled trial (CCT) were used for comparing apatinib with placebo, and two retrospective clinical studies (RCSs) were used for comparing apatinib with sorafenib. Apatinib led to higher overall effects in objective response rate (ORR), disease control rate (DCR), and mean survival time (MST) over placebo (RR = 2.03, 95% CI = 1.46–2.81, p < 0.0001, I2 = 0%; RR = 1.17, 95% CI = 1.04–1.33, p = 0.009, I2 = 45.8%; SMD = 2.63; 95% CI = 1.47–3.78, p < 0.0001, I2 = 92.7%, respectively). Compared to sorafenib, apatinib showed no superiority in ORR and DCR but was inferior in the 6-month and 1-year survival rate (RR = 1.99, 95% CI = 0.85–4.65, p = 0.111, I2 = 68.3%; RR = 1.04, 95% CI = 0.73–1.47, p = 0.840, I2 = 0.0%; RR = 0.63, 95% CI = 0.42–0.97, p = 0.036, I2 = 0.0%; RR = 0.47, 95% CI = 0.29–0.79, p < 0.0001, I2 = 0.0%, respectively). Apatinib had similar adverse effects over placebo but possessed a greater incidence rate of proteinuria and hypertension over sorafenib. Conclusion: In the first-line setting, apatinib might be an alternative treatment approach for patients with intermediate and advanced PLC. Sorafenib alone showed a better survival rate within 1 year and a lower incidence rate in hypertension and proteinuria than apatinib monotherapy.

[1]  Lu Xu,et al.  Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study , 2022, Frontiers in Immunology.

[2]  P. Leone,et al.  The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment , 2021, Vaccines.

[3]  J. Llovet,et al.  Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Murad,et al.  Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. , 2020, JAMA oncology.

[5]  Jianming Xu,et al.  Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.

[6]  J. Bruix,et al.  Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. , 2020, Clinics in liver disease.

[7]  Yun-fei Yuan,et al.  Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study , 2020, Annals of translational medicine.

[8]  M. Kudo,et al.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Xiaoxiao He,et al.  Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-κB Signaling Pathway , 2020, BioMed research international.

[10]  Yulei N. Wang,et al.  Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. , 2020, The Lancet. Oncology.

[11]  J. Aitken,et al.  Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis , 2020, Frontiers in Oncology.

[12]  F. Kiessling,et al.  Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma , 2019, Hepatology.

[13]  Yan Wei,et al.  Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis , 2019, Chemotherapy.

[14]  Guangji Wang,et al.  Apatinib induces 3‐hydroxybutyric acid production in the liver of mice by peroxisome proliferator‐activated receptor α activation to aid its antitumor effect , 2019, Cancer science.

[15]  Yonghao Yang,et al.  Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report. , 2019, Immunotherapy.

[16]  Z. Meng,et al.  A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. , 2019, Journal of Clinical Oncology.

[17]  K. McGlynn,et al.  The Changing Epidemiology of Primary Liver Cancer , 2019, Current Epidemiology Reports.

[18]  F. Hirsch,et al.  Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer , 2019, Cancer Immunology Research.

[19]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[20]  jinmin xue,et al.  Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis , 2018, OncoTargets and therapy.

[21]  H. Pan,et al.  The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study , 2018, Journal of Cancer.

[22]  Yizhuo Wang,et al.  Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study , 2018, OncoTargets and therapy.

[23]  N. Mukaida,et al.  Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma , 2018, World journal of gastroenterology.

[24]  L. Scott.  Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers , 2018, Drugs.

[25]  Hua Zhang,et al.  Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway , 2018, Oncology letters.

[26]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[27]  P. Tschandl,et al.  Driver mutations in the mitogen‐activated protein kinase pathway: the seeds of good and evil , 2018, The British journal of dermatology.

[28]  L. Dyck,et al.  Immune checkpoints and their inhibition in cancer and infectious diseases , 2017, European journal of immunology.

[29]  S. Steinberg,et al.  Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. , 2017, Journal of hepatology.

[30]  Xiangxuan Zhao,et al.  Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells , 2016, Innate immunity.

[31]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[32]  M. Lacouture,et al.  Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Ragaz,et al.  Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer , 2014, International journal of cancer.

[34]  B. McLellan,et al.  Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. , 2014, Journal of the American Academy of Dermatology.

[35]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[36]  H. Hurwitz,et al.  Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression , 2009, Hypertension.

[37]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[38]  C. Alpers,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[39]  H. Izzedine,et al.  Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  P. Fisher,et al.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. , 2021, Advances in cancer research.

[41]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[42]  Chih-Ping Chen,et al.  Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery , 2003, Annals of Surgical Oncology.